Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (12343)	12/9/1997 8:00:00 AM
From: Henry Niman	Respond to of 32384

Andy, I suspect that the Business Week article will come out next week, but I'm not sure. However, I have had a chance to read the online article and its really about as good as it gets. LGND's treatment was the centerpiece of the article and investors who look into the AGN connection should find out that LGND gets a 6% royalty on those drugs also. The third article targets the largest readership, and will help Ligand become a household name. I was impressed with the breadth and timing of the three publications. The fact that all three were being prepared at the same time was significant, and an indication that LGND's PR firm is finally starting to earn its pay. Keep in mind that no human data has been released yet, but LGND's program is just beginning to get some significant popular press coverage. I expect LLY to jump into the clinic with both feet (montherapy as well as combinations with insulin, TZDs, sulfnylureas, and Metformin). You ain't seen nothin' yet.